



### **Financial Services**

Report Code: GDFS4572388FA Published: October 2023

# Blue Owl Capital Inc (OWL) - Financial Analysis Review



### **Company Snapshot**

399 Park Avenue, 37th Floor	Phone	+1 212 4193000	Revenue	1,369.7 (million USD)
New York, NY	Fax	+1 302 6555049	Net Profit	-9.29 (million USD)
10022	Website	www.blueowl.com	Employees	545 (Estimated)
United States	Exchange	OWL [New York Stock Exchange]	Industry	Financial Services

#### **Company Overview**

Blue Owl Capital Inc (Blue Owl) is a finance and business development company that provides lending solutions. The company operates through its platform such as credit, GP Strategic capital and real estate. its credit executes and manages investments across various loan and equity-related instruments, gp strategic capital providing long-term minority equity and financing. Blue Owl provides flexible real estate solutions. It provides solutions to middle-market companies including alternative asset managers, financial advisors, growth tech companies and institutional investors, among others. The company operates in the US, the UK, Malta, Hong Kong, Singapore and the Cayman Islands.

#### **Kev Executives**

, =	
Name	Title
Douglas I. Ostrover	Chairman
Marc S. Lipschultz	Co-President
Michael Rees	Co-President
Craig W. Packer	Co-President
Sean Ward	Director

Source: Annual Report, Company Website, Primary and Secondary Research, GlobalData

#### Share Data


Blue Owl Capital Inc	
Price (USD) as on 06-Oct-2023	13.70
EPS (USD)	-0.01
Market Cap (million USD)	19,208
Enterprise Value (million USD)	24,709
Shares Outstanding (million)	1,407

Source: Annual Report, Company Website, Primary and Secondary Research, Global Data

#### **Key Competitors**

Name
The Carlyle Group Inc.
Cannae Holdings Inc
Brookfield Corp
Source: Annual Report, Company Website, Primary and Secondary Research,
GlobalData

#### **Financial Performance**



Source: Annual Report, Company Website, Primary and Secondary Research, GlobalData



### **Table of Contents**

Table of Contents	3
List of Tables	4
List of Figures	4
Section 1 - About the Company	5
Blue Owl Capital Inc - Key Facts	5
Blue Owl Capital Inc - Key Employees	
Blue Owl Capital Inc - Major Products and Services	
Blue Owl Capital Inc - History – Overall (4)	
Blue Owl Capital Inc - History – Mergers & Acquisitions (4)	
Blue Owl Capital Inc - History – Expansion (1)	
Blue Owl Capital Inc - Locations And Subsidiaries	
Head Office	
Other Locations & Subsidiaries	
Section 2 – Company Analysis	
Company Overview	
Blue Owl Capital Inc - Key Competitors	
Section 3 – Key Companies Snapshot	
Brookfield Corp (BN) - Key Facts	
Brookfield Corp (BN) - Company Overview	
Brookfield Corp (BN) - Key Recent Developments	
The Carlyle Group Inc. (CG) - Key Facts	
The Carlyle Group Inc. (CG) - Company Overview	
The Carlyle Group Inc. (CG) - Key Recent Developments	
Cannae Holdings Inc (CNNE) - Key Facts	
Cannae Holdings Inc (CNNE) - Company Overview	
Section 4 – Company Financial Ratios	
Financial Ratios - Capital Market Ratios	
Financial Ratios - Annual Ratios	
Performance Chart	
Financial Performance	
Financial Ratios - Interim Ratios	
Financial Ratios - Ratio Charts	
Section 5 – Company's Mergers & Acquisitions, Capital Raising and Alliances	
Blue Owl Capital Inc, Transactions by Year, 2017 to YTD 2023	
Blue Owl Capital Inc, Transactions by Type, 2017 to YTD 2023	
Blue Owl Capital Inc, Transactions by Type, 2017 to YTD 2023	
Blue Owl Capital Inc, Private Equity/Venture Capital Transactions, 2017 to YTD 2023	
Blue Owl Capital Inc, Recent Transactions Summary	
Debt Offerings	
ADC Therapeutics Raises USD175 Million in Private Placement of Senior Secured Term Loan due 2029	
Private Equity	
TSG Consumer Partners Invests in Specialty Dental Brands	
Section 6 – Appendix	
Methodology	
Ratio Definitions	
About GlobalData	
Contact Us	
Disclaimer	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,



### List of Tables

Blue Owl Capital Inc, Key Facts	
Blue Owl Capital Inc, Key Employees	
Blue Owl Capital Inc, Major Products and Services	
Blue Owl Capital Inc - History – Overall (4)	
Blue Owl Capital Inc - History – Mergers & Acquisitions (4)	
Blue Owl Capital Inc - History – Expansion (1)	
Blue Owl Capital Inc, Other Locations	
Blue Owl Capital Inc, Subsidiaries	
Blue Owl Capital Inc, Key Competitors	
Brookfield Corp (BN) - Key Facts	
The Carlyle Group Inc. (CG) - Key Facts	
Cannae Holdings Inc (CNNE) - Key Facts	
Blue Owl Capital Inc, Ratios based on current share price	
Blue Owl Capital Inc, Annual Ratios	
Blue Owl Capital Inc, Annual Ratios (Cont1)	
Blue Owl Capital Inc, Interim Ratios	
Blue Owl Capital Inc, Transactions by Year, 2017 to YTD 2023	
Blue Owl Capital Inc, Transactions by Type, 2017 to YTD 2023	
Blue Owl Capital Inc, Transactions by Region, 2017 to YTD 2023	
Blue Owl Capital Inc, Private Equity/Venture Capital Transactions, 2017 to YTD 2023	
Blue Owl Capital Inc, Recent Transactions Summary	
Currency Codes	
Capital Market Ratios	
Equity Ratios	
Profitability Ratios	
Cost Ratios	
Liquidity Ratios	
Leverage Ratios	
Efficiency Ratios	36
List of Figures	
Blue Owl Capital Inc, Performance Chart (2018 - 2022)	
Blue Owl Capital Inc, Ratio Charts	
Blue Owl Capital Inc, Transactions by Year, 2017 to YTD 2023	
Blue Owl Capital Inc, Transactions by Type, 2017 to YTD 2023	
Blue Owl Capital Inc, Transactions by Region, 2017 to YTD 2023	
Blue Owl Capital Inc, Private Equity/Venture Capital Transactions, 2017 to YTD 2023	27



### Section 1 - About the Company

### Blue Owl Capital Inc - Key Facts

Blue Owl Capital Inc, Key Facts				
Corporate Address	399 Park Avenue, 37th Floor, New York, NY, 10022, United States	Ticker Symbol, Exchange	OWL [New York Stoc	k Exchange]
Telephone	+1 212 4193000	No. of Employees	545 (Estimated)	
Fax	+1 302 6555049	Fiscal Year End	December	
URL	www.blueowl.com	Revenue (in USD Million)	1,369.7	
Industry	Financial Services			
Locations	Canada, Hong Kong, United Kingo	dom, United States		
Source: Annual Report, Company Website, Primary and Secondary Research Glob			GlobalData	



### Blue Owl Capital Inc - Key Employees

Blue Owl Capital Inc, Key Employees				
Name	Job Title	Board Level	Since	Age
Douglas I. Ostrover	Chairman, Chief Executive Officer, Director	Executive Board	2021	60
Marc S. Lipschultz	Co-President, Director	Executive Board	2021	54
Michael Rees	Co-President, Director	Executive Board	2021	48
Craig W. Packer	Co-President, Director	Executive Board	2021	56
Sean Ward	Director, Senior Managing Director	Executive Board	2021	44
Marc Zahr	Director, President Real Estate Division	Executive Board	2021	43
Dana Weeks	Director	Non Executive Board	2021	52
Claudia Holz	Director	Non Executive Board	2021	65
Andrew S. Komaroff	Director	Non Executive Board	2021	54
Stacy Polley	Director	Non Executive Board	2021	54
Alan Kirshenbaum	Chief Financial Officer	Senior Management		51
Andrew Polland	Chief Operating Officer	Senior Management		48
Andrew Laurino	Senior Managing Director	Senior Management		47
Neena A. Reddy	General Counsel, Secretary	Senior Management		45
Chris Crampton	Managing Director	Senior Management	2023	
Source: Annual Report, Company Website, Primary and Secondary Research Global G			GlobalData	



### Blue Owl Capital Inc - Major Products and Services

Blue Owl provides investment services. The company's major services include the following:

### Blue Owl Capital Inc, Major Products and Services

Services:

Asset Management and Investment

Financing

**Direct Lending** 

Source: Annual Report, Company Website, Primary and Secondary Research



### Blue Owl Capital Inc - History - Overall (4)

Blue Owl Capital Inc - History – Overall (4)		
2023	Financing Agreements	In July, the company's GP Strategic Capital platform made a passive, minority investment in Stonepeak.
2022	New Products/Services	In January, the company announced the launch of U.S. direct lending capabilities to Canadian investors.
2022	New Products/Services	In May, the company launched a private-credit vehicle.
2009	Incorporation/Establishment	The company was founded.
Source: Annual Report, Company Website, Primary and Secondary Research  GlobalData		



### Blue Owl Capital Inc - History - Mergers & Acquisitions (4)

Blue Owl Capital Inc - History – Mergers & Acquisitions (4)		
2022	Acquisitions/Mergers/Takeovers	In April, the company acquired Wellfleet Credit Partners from Littlejohn & Co.
2022	Acquisitions/Mergers/Takeovers	In January, the company acquired an almost six percent (6%) equity stake in the Atlanta Hawks from nine existing minority shareholders.
2021	Acquisitions/Mergers/Takeovers	In December, the company acquired Ascentium Group Limited, a business equipment financing and leasing company.
2021	Acquisitions/Mergers/Takeovers	In December, the company completed the acquisition of Oak Street Real Estate Capital, LLC.
Source: Annual Report, Company Website, Primary and Secondary Research Global Data		



### Blue Owl Capital Inc - History — Expansion (1)

### Blue Owl Capital Inc - History – Expansion (1)

2022 Corporate Changes/Expansions

In May, the company launched Owl Rock Technology Income Corporation, a non-traded business development company.

Source: Annual Report, Company Website, Primary and Secondary Research



### Blue Owl Capital Inc - Locations And Subsidiaries

### **Head Office**

Blue Owl Capital Inc

399 Park Avenue, 37th Floor

New York

NY

10022

**United States** 

Tel: +1 212 4193000 Fax: +1 302 6555049

### Other Locations & Subsidiaries

Blue Owl Capital Inc, Other Locations	
16 Berkeley StreetLondon	2884 Sandhill RoadMenlo Park
,	California
W1J 8DZ	94025
United Kingdom	United States
51 John F. Kennedy ParkwayShort Hills	646 Steamboat RoadGreenwich
New Jersey	Connecticut
07078	06830
United States	United States

Source: Annual Report, Company Website, Primary and Secondary Research

Blue Owl Capital Carry LP
United States
Blue Owl Capital Holdings LLC
United States
Blue Owl Securities LLC
United States
Dyal Capital Holdings LLC
United States
Dyal Earl GP LLC
United States
Dyal HomeCourt Associates LLC United States



Dyal Horizon GP LLC United States

NB Dyal Columbus GP LLC

**United States** 

Oak Street Real Estate Capital LLC

Suite 1220 125 S. Wacker Drive

Chicago IL 60606 United States

Url: www.oakstreetrec.com

Owl Rock Capital Diversified Holdings LLC

**United States** 

Owl Rock Capital Group LLC

**United States** 

Owl Rock Capital Technology Holdings LLC

**United States** 

Dyal UK Ltd United Kingdom

NB James GP LLC United States

Owl Rock Capital Advisors LLC

**United States** 

Owl Rock Capital GP Holdings LP

**United States** 

Owl Rock Capital Private Fund Advisors LLC

**United States** 

Wellfleet Credit Partners, LLC

MA

**United States** 

Source: Annual Report, Company Website, Primary and Secondary Research



### Section 2 - Company Analysis

### **Company Overview**

Blue Owl Capital Inc (Blue Owl) is a finance and business development company that provides lending solutions. The company operates through its platform such as credit, GP Strategic capital and real estate. its credit executes and manages investments across various loan and equity-related instruments, gp strategic capital providing long-term minority equity and financing. Blue Owl provides flexible real estate solutions. It provides solutions to middle-market companies including alternative asset managers, financial advisors, growth tech companies and institutional investors, among others. The company operates in the US, the UK, Malta, Hong Kong, Singapore and the Cayman Islands. Blue Owl is headquartered in New York, the US.



### Blue Owl Capital Inc - Key Competitors

Blue Owl Capital Inc, Key Competitors		
Name	Headquarters	Revenue (US\$ m)
Brookfield Corp	Canada	92,769
The Carlyle Group Inc.	United States	4,439
Cannae Holdings Inc	United States	662
Source: Annual Report, Company Website, Primary and Secondary Research		GlobalData



### Section 3 – Key Companies Snapshot

### Brookfield Corp (BN) - Key Facts

Brookfield Corp (BN) - Key Facts			
Corporate Address	Brookfield Place, 181 Bay St, Ste 100,, Po Box 762, Toronto, ON, M5J2T3, Canada	Ticker Symbol, Exchange	BN [New York Stock Exchange]
Telephone	+1 416 3639491	No. of Employees	200,000
Fax	+1 416 3659642	Fiscal Year End	December
URL	www.brookfield.com	Revenue (in USD Million)	92,769
Industry	Construction & Real Estate, Energy and Utilities, Financial Services, Industrial Goods and Machinery		
Locations	Australia, Bermuda, Brazil, Canad Kingdom, United States	da, China, Hong Kong, India, Spa	in, United Arab Emirates, United
Source: Annual Report, Company We	ebsite, Primary and Secondary Research		GlobalData

### Brookfield Corp (BN) - Company Overview

Brookfield Corp (Brookfield) is an alternative asset manager. It owns, operates, and invests in assets across real estate, renewable energy and power, infrastructure, and private equity. The company provides a wide range of public and private investment products and services to its investors, including private funds, listed issuers, and public securities. It also offers structured transaction services. It also provides worldwide platform to assist businesses and governments in achieving their carbon reduction objectives. Brookfield operates in the EMEA, the Americas, and the Asia Pacific through its corporate offices in the US, Canada, the UK, India, China, the UAE, Australia, Colombia, and Brazil. Brookfield is headquartered in Toronto, Ontario, Canada.

### Brookfield Corp (BN) - Key Recent Developments

Brookfield Corp, Recent Developments	
Sep 14,2023	Karthik Rao Named CEO of Nielsen
Jun 16,2023	Natural Power Supports Brookfield's \$2.8 Billion Investment in Duke Energy Renewables
May 11,2023	Brookfield announces financial results for quarter ended March 31, 2023
Apr 25,2023	G&W Announces Leadership Changes
Mar 24,2023	Brookfield Residential Yard Refuse Center - Opening April 15, 2023

Source: Annual Report, Company Website, Primary and Secondary Research, GlobalData



### The Carlyle Group Inc. (CG) - Key Facts

The Carlyle Group Inc. (CG) - Key Facts					
Corporate Address	C/O The Carlyle Group, 1001 Pennsylvania Avenue, N.W., Washington, DC, 20004, United States	Ticker Symbol, Exchange	CG [NASDAQ]		
Telephone	+1 202 7295626	No. of Employees	2,100		
Fax	+1 302 6555049	Fiscal Year End	December		
URL	www.carlyle.com	Revenue (in USD Million)	4,438.7		
Industry	Energy and Utilities, Financial Services				
Locations	India, Indonesia, Ireland, Israel,	taly, Japan, Luxembourg, Maurit	ot, France, Germany, Hong Kong, ius, Mexico, Netherlands, Nigeria, vitzerland, United Arab Emirates,		
Source: Annual Report, Company W	ebsite, Primary and Secondary Research		GlobalData		

### The Carlyle Group Inc. (CG) - Company Overview

The Carlyle Group Inc. (Carlyle) is a global alternative asset management, private equity, and financial services firm. The group advises specialized investment funds and other investment vehicles that invest across various industries, geographies, asset classes, and investment strategies. Carlyle has expertise in industries including aerospace, defense and government services, consumer and retail, energy, financial services, healthcare, industrial, real estate, technology and business services, telecommunications and media, and transportation. Its investors include public and private pension funds, high net-worth individuals, insurance companies, families, and sovereign wealth funds. The group has operations across North America, South America, Europe, the Middle East, and Asia. Carlyle is headquartered in Washington DC, the US.

### The Carlyle Group Inc. (CG) - Key Recent Developments

The Carlyle Group Inc., Recent Develo	opments
Oct 02,2023	Carlyle Names Jeff Nedelman as Global Head of Distribution
Sep 05,2023	Amp executes BESS Connection Agreement for its Bungama Battery in South Australia
Aug 16,2023	France's M&P to acquire Gabon oil company Assala for \$730m
Aug 03,2023	Carlyle Announces Q2 2023 Financial Results
Jul 18,2023	Carlyle Appoints Lucia Soares as Chief Information Officer and Head of Technology Transformation

Source: Annual Report, Company Website, Primary and Secondary Research, GlobalData



### Cannae Holdings Inc (CNNE) - Key Facts

Cannae Holdings Inc (CNNE) - Key Facts					
Corporate Address	1701 Village Center Cir, Las Vegas, NV, 89134-6368, United States	Ticker Symbol, Exchange	CNNE [New Exchange]	York Stock	
Telephone	+1 702 3237334	No. of Employees	11,988		
Fax	+1 302 6555049	Fiscal Year End	December		
URL	www.cannaeholdings.com	Revenue (in USD Million)	662.1		
Industry	Financial Services				
Locations	United States				
Source: Annual Report, Company Website, Primary and Secondary Research					

### Cannae Holdings Inc (CNNE) - Company Overview

Cannae Holdings Inc (Cannae Holdings) is a diversified holding company. Its investments in various industries include technology-enabled healthcare services, financial services, restaurants, and others. It has majority and minority equity investment stakes in Ceridian Holdings LLC, American Blue Ribbon Holdings LLC, and T-System Holding LLC. Cannae Holdings conducts its business primarily through its subsidiary Cannae Holdings LLC. The company operates across the US. Cannae Holdings is headquartered in Las Vegas, Nevada, the US.



### Section 4 – Company Financial Ratios

### Financial Ratios - Capital Market Ratios

Blue Owl Capital Inc, Ratios based on current share price				
Key Ratios	06-Oct-2023			
EV/EBITDA (Enterprise Value/Earnings Before Interest, Taxes, Depreciation and Amortization)	117.89			
Enterprise Value/Sales	18.04			
Enterprise Value/Total Assets	2.78			
Dividend Yield	0.95			
Note: Above ratios are based on share price as of 06-Oct-2023, the above ratios are absolute numbers				
Source: Annual Report, Company Website, Primary and Secondary Research	GlobalData			



### Financial Ratios - Annual Ratios

Blue Owl Capital Inc, Annual Ratios						
Key Ratios	Unit/Currency	2018	2019	2020	2021	2022
Equity Ratios						
EPS (Earnings per Share)	USD	0.01	0.06	-0.22	-0.92	-0.01
Dividend per Share	USD				0.13	0.43
Dividend Cover	Absolute				-7.11	-0.02
Book Value per Share	USD		-0.27	-0.38	1.19	1.15
Cash Value per Share	USD		0.01	0.01	0.03	0.05
Profitability Ratios						
Operating Margin	%	-1.35	14.34	-23.51	-114.69	-0.18
Net Profit Margin	%	1.69	12.03	-31.16	-45.66	-0.68
PBT Margin (Profit Before Tax)	%	-2.28	10.85	-33.04	-226.67	-3.62
Return on Equity	%		-6.51	15.33	-22.61	-0.58
Return on Capital Employed	%		48.25	-48.30	-11.43	-0.03
Return on Assets	%		80.95	-87.30	-8.97	-0.11
Return on Fixed Assets	%		1,620.79	-1,744.45	-1,941.45	-1.27
Return on Working Capital	%			-26.38		
<b>Growth Ratios</b>						
Sales Growth	%		57.40	30.90	229.80	66.25
Operating Income Growth	%		1,769.74	-314.59	-1,508.98	99.74
EBITDA Growth	%			-305.89		
Net Income Growth	%		1,021	-439.01	-383.32	97.53




Blue Owl Capital Inc, Annual Ratios (						
Key Ratios	Unit/Currency	2018	2019	2020	2021	2022
EPS Growth	%		1,021.64	-439.02	-324.32	99.16
Cost Ratios						
Operating Costs (% of Sales)	%	101.35	85.66	123.51	214.69	100.18
Administration Costs (% of Sales)	%	101.35	85.66	123.51	191.90	80.76
Liquidity Ratios						
Current Ratio	Absolute			8.99		
Quick Ratio	Absolute			8.99		
Cash Ratio	Absolute			6.54		
Leverage Ratios						
Debt to Equity Ratio	%		-0.81	-0.70	0.71	1.01
Net Debt to Equity	Absolute		-0.79	-0.68	0.68	0.97
Debt to Capital Ratio	%		-4.37	-2.36	0.41	0.50
Efficiency Ratios						
Asset Turnover	Absolute		6.73	2.80	0.20	0.16
Fixed Asset Turnover	Absolute		113.03	74.21	16.93	7.03
Capital Employed Turnover	Absolute		3.36	2.05	0.10	0.15
Revenue per Employee	USD					2,513,251
Net Income per Employee	USD					-17,044
Capex to Sales	%	2.62	0.61	0.26	0.64	4.78
Source: Annual Report, Company Website	e, Primary and Secondary Researd	ch				GlobalDa



### **Performance Chart**





Source: Annual Report, Company Website, Primary and Secondary Research

GlobalData

### **Financial Performance**

The company reported revenues of (US Dollars) US\$1,369.7 million for the fiscal year ended December 2022 (FY2022), an increase of 66.3% over FY2021. The operating loss of the company was US\$2.5 million in FY2022, compared to an operating loss of US\$944.9 million in FY2021. The net loss of the company was US\$9.3 million in FY2022, compared to a net loss of US\$376.2 million in FY2021.

The company reported revenues of US\$416.9 million for the second quarter ended June 2023, an increase of 6.6% over the previous quarter.




### Financial Ratios - Interim Ratios

Blue Owl Capital Inc, Interim Ratios						
Key Ratios	Unit/Currency	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023
Interim EPS (Earnings per Share)	USD				0.02	0.03
Dividend per Share	USD	0.10	0.11	0.12	0.13	0.14
Book Value per Share	USD	1.16	1.18	1.15	1.13	1.12
Operating Margin	%	-3.10	0.66	7.07	16.97	9.90
Net Profit Margin	%	-0.34	0.56	0.40	2.13	3.08
PBT Margin (Profit Before Tax)	%	-1.05	-3.80	-1.04	12.40	9.46
Operating Costs (% of Sales)	%	103.10	99.34	92.93	83.03	90.10
Administration Costs (% of Sales)	%	80.10	81.12	79.79	64.87	61.42
Current Ratio	Absolute				8.99	11.78
Quick Ratio	Absolute				8.99	11.78
Debt to Equity Ratio	%	0.87	0.92	1.01	1.11	1.12
Net Debt to Equity	Absolute	0.84	0.90	0.97	1.09	1.09
Debt to Capital Ratio	%	0.17	0.17	0.18	0.20	0.20
Source: Annual Report, Company Website, Primary and Secondary Research  GlobalE						GlobalData





### **Financial Ratios - Ratio Charts**





### Section 5 – Company's Mergers & Acquisitions, Capital Raising and Alliances Blue Owl Capital Inc, Transactions by Year, 2017 to YTD 2023





Note: Deals include all announced deals from 2017 onwards, deal values included wherever disclosed. Above data is extracted from GlobalData's Deals and Alliances Profile.

GlobalData


Blue Owl Capital Inc's, deal volume increased from zero deals in 2021 to two deals in 2022. No deals were reported by the company in YTD 2023.

Blue Owl Capital Inc, Transactions b	y Year, 2017 to YTD 2023			
YEAR	No. of Deals	Deal Value (US\$ million)		
2017	0	NA		
2018	0	NA		
2019	0	NA		
2020	0	NA		
2021	0	NA		
2022	2	175.00		
YTD 2023	0	NA		
Note: Deals include all announced deals from 2017 onwards, deal values included wherever disclosed. Above data is extracted from GlobalData's Deals and Alliances Profile.				



### Blue Owl Capital Inc, Transactions by Type, 2017 to YTD 2023

### Blue Owl Capital Inc, Transactions by Type, 2017 to YTD 2023




Note: Deals include all announced deals from 2017 onwards Above data is extracted from GlobalData's Deals and Alliances Profile. GlobalData

Blue Owl Capital Inc reported one deals each in Debt Offerings, Private Equity during the period 2017 to YTD 2023.

Blue Owl Capital Inc, Transactions by Type, 2017 to YTD 2023					
Deal type	No. of Deals	Deal Value (US\$ million)			
Debt Offerings	1	175.00			
Private Equity	1	0.00			
Note: Deals include all announced deals from 20 from GlobalData's Deals and Alliances Profile.	017 onwards, deal values included wherever disclosed. Abo	ove data is extracted GlobalData			



### Blue Owl Capital Inc, Transactions by Region, 2017 to YTD 2023



Note: Deals include all announced deals from 2017 onwards, deal values included wherever disclosed. Above data is extracted from GlobalData's Deals and Alliances Profile.

GlobalData


Blue Owl Capital Inc, reported one deal in Middle East and Africa, and North America during the period 2017 to YTD 2023.

Blue Owl Capital Inc, Transactions by Region, 2017 to YTD 2023		
Region	No. of Deals	Deal Value (US\$ million)
Middle East and Africa	1	175.00
North America	1	NA
Note: Deals include all announced deals from 201 from GlobalData's Deals and Alliances Profile.	7 onwards, deal values included wherever disclosed. Ab	ove data is extracted GlobalData



### Blue Owl Capital Inc, Private Equity/Venture Capital Transactions, 2017 to YTD 2023

### Blue Owl Capital Inc, Private Equity/Venture Capital Transactions, 2017 to YTD 2023



Note: Deals include all announced deals from 2017 onwards, deal values included wherever disclosed. Above data is extracted from GlobalData's Deals and Alliances Profile.

GlobalData

Blue Owl Capital Inc's Private Equity/Venture Capital segment reported zero deals in YTD 2023. In 2022, there was one deal worth undisclosed deal value.

Blue Owl Capital Inc, Private Equity/Venture Capital Transactions, 2017 to YTD 2023		
YEAR	No. of Deals	Deal Value (US\$ million)
2017	0	NA
2018	0	NA
2019	0	NA
2020	0	NA
2021	0	NA
2022	1	NA
YTD 2023	0	NA
Note: Deals include all announced deals from 2017 onwards, deal values included wherever disclosed. Above data is extracted from GlobalData's Deals and Alliances Profile.		



### Blue Owl Capital Inc, Recent Transactions Summary

Blue Owl Capital Inc, Recent Transactions Summary				
Deal Date	Deal type	Deal Status	Deal Headline	Deal Value (US \$ million
19-Sep-2022	Private Equity	Completed	TSG Consumer Partners Invests in Specialty Dental Brands	
15-Aug-2022	Debt Offerings	Announced	ADC Therapeutics Raises USD175 Million in Private Placement of Senior Secured Term Loan due 2029	175.00
		2017 onwards, deal value als and Alliances Profile.	es included wherever disclosed.	GlobalData



### **Debt Offerings**

## ADC Therapeutics Raises USD175 Million in Private Placement of Senior Secured Term Loan due 2029

Deal Type Deal in Brief			
Deal in Brief	Debt Offering	Deal Sub Type	Private Placement
secured term loan with certain fu Management, L.P. (Oaktree) with aggregate principal amount of sen \$117.3 million in cash including the value of the remaining interest of 4,412,840 common shares at exercicular with the common shares for hematologic support from the common shares for the ten trading the common shares for the ten trading exercicable for ten years from the common shares for the ten trading exercicular with the common shares	hat it has completed a series of strands of Owl Rock, a division of Blue in an upfront tranche of USD120 representation of transport of the contractual exit fee on principal representation of the convertible debenture due on the convertible debenture due on the convertible debenture divided on the convertible debenture divided by Period (Series) of \$24.70 and \$28.07 per divided by Deerfield," said Ameet Mallifubles us to continue maximizing the malignancies and solid tumors. They positive, and we are pleased to make." Pursuant to the loan and gual 22. This amount was used by the Catible notes. Up to two additional transportant in the same (SOFR) plus 7.50% or a base rate rate plus 8.25% thereafter. In addition of common shares equal to USD and days prior to their issuance and series sector expertise and tailored ased to invest in ADC Therapeutics' or therapies including ZYNLONTA." To hematologic malignancies and so contant time in the Company's development of the company's development.	Owl Capital, Inc. (Owl Rock), and familion received upon closing todatory Deerfield Management Company repayment, (ii) 2,390,297 common to the end of term, and (iii) warreshare; Entered into a share purchase 25 million for 733,568 common shawill be used to pay the cash conk, Chief Executive Officer of ADC The potential of ZYNLONTA and advance continued equity support of Detaintain our cash runway into early arranty agreement, the Company company to fund the cash consider anches in the amount of USD27.5 million divided by the voluntate that the Company issued to the lend 4.375 million divided by the voluntate that the trading days on and after the aging Director with Owl Rock commulti-security approach to help prostrong team, portfolio and track rewe are excited to partner with AE olid tumors," said Aman Kumar, Colopment with its first product approach to the prostrong team, portfolio and track reweare excited to partner with AE olid tumors," said Aman Kumar, Colopment with its first product approach to the prostrong team, portfolio and track reweare excited to partner with AE olid tumors," said Aman Kumar, Colopment with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with its first product approach to the prostrong team with the prostrong team with the prostrong team	unds managed by Oaktree Capita y;Settled in full the \$115 million ("Deerfield") due May 2025 for (is shares approximately equal to the ants to purchase an aggregate of seagreement with certain funds of ares. "We are pleased to enter into sideration in the exchange of the terapeutics. "This new debt facility cing our pipeline of novel antibody erfield and the additional equity 2025 as this deal is approximately ompleted an initial drawdown of attended and accrues interest at an annual of the term loans and at an annual of the term loans and at an annual ders under the term loan warrants are mented, "This transaction display ovide growth capital to companie ecord of success in developing and of Therapeutics as it continues to Portfolio Manager of Life Science.
platform. This commitment of cap with the Company's leadership to Deerfield said: "We have been a some the IPO and also providing the correpayment consideration in ADCT acted as the sole placement agent Deal Rationale  ADC Therapeutics intends to use to	eam during this next phase of grow upporter of ADC Therapeutics datin nvertible debenture that is being re- stock and look forward to continuing to ADC Therapeutics on this transact the net proceeds to continue maximatologic malignancies and solid turn	wth. "Elise Wang, Partner, Head of g back to its successful IPO in May etired today. We are very pleased ing to support the company going fection.  Alizing the potential of ZYNLONTA and are respectively.	Private Equity Capital Markets as 2020 as both an equity investor in to take a significant portion of the prward." Morgan Stanley & Co. LLC
platform. This commitment of cap with the Company's leadership to Deerfield said: "We have been as the IPO and also providing the corepayment consideration in ADCT acted as the sole placement agent Deal Rationale  ADC Therapeutics intends to use the antibody drug conjugates for hem.	eam during this next phase of grow upporter of ADC Therapeutics datin nvertible debenture that is being re stock and look forward to continuing to ADC Therapeutics on this transaction.	wth. "Elise Wang, Partner, Head of g back to its successful IPO in May etired today. We are very pleased ing to support the company going fection.  Alizing the potential of ZYNLONTA and are respectively.	Private Equity Capital Markets as 2020 as both an equity investor in to take a significant portion of the prward." Morgan Stanley & Co. LLC
platform. This commitment of cap with the Company's leadership to Deerfield said: "We have been a state IPO and also providing the correpayment consideration in ADCT acted as the sole placement agent Deal Rationale  ADC Therapeutics intends to use to antibody drug conjugates for hemodeal Information	eam during this next phase of grow upporter of ADC Therapeutics datin nvertible debenture that is being re- stock and look forward to continuing to ADC Therapeutics on this transact the net proceeds to continue maximatologic malignancies and solid turn	wth. "Elise Wang, Partner, Head of g back to its successful IPO in May etired today. We are very pleased ing to support the company going fection.  Alizing the potential of ZYNLONTA and are respectively.	Private Equity Capital Markets as 2020 as both an equity investor in to take a significant portion of the prward." Morgan Stanley & Co. LLC
platform. This commitment of cap with the Company's leadership to Deerfield said: "We have been a state IPO and also providing the correpayment consideration in ADCT acted as the sole placement agent Deal Rationale  ADC Therapeutics intends to use to antibody drug conjugates for hemodeal Information  Deal Status  Announced Date	eam during this next phase of growupporter of ADC Therapeutics dating invertible debenture that is being restock and look forward to continuit to ADC Therapeutics on this transaction in the net proceeds to continue maximatologic malignancies and solid tum.	wth. "Elise Wang, Partner, Head of g back to its successful IPO in May etired today. We are very pleased ing to support the company going fection.  Alizing the potential of ZYNLONTA and are respectively.	Private Equity Capital Markets as 2020 as both an equity investor in to take a significant portion of the prward." Morgan Stanley & Co. LLC
platform. This commitment of cap with the Company's leadership to Deerfield said: "We have been a sthe IPO and also providing the corepayment consideration in ADCT acted as the sole placement agent Deal Rationale  ADC Therapeutics intends to use to antibody drug conjugates for hemodeal Information  Deal Status  Announced Date  Deal Financials	eam during this next phase of growupporter of ADC Therapeutics dating invertible debenture that is being restock and look forward to continuit to ADC Therapeutics on this transaction in the net proceeds to continue maximatologic malignancies and solid tum.	wth. "Elise Wang, Partner, Head of g back to its successful IPO in May etired today. We are very pleased ing to support the company going fection.  Alizing the potential of ZYNLONTA and are respectively.	Private Equity Capital Markets as 2020 as both an equity investor in to take a significant portion of the prward." Morgan Stanley & Co. LLC
platform. This commitment of cap with the Company's leadership to Deerfield said: "We have been a sthe IPO and also providing the correpayment consideration in ADCT acted as the sole placement agent Deal Rationale  ADC Therapeutics intends to use to antibody drug conjugates for hemodeal Information  Deal Status  Announced Date  Deal Financials  Deal Value (US\$ m)	eam during this next phase of grovupporter of ADC Therapeutics datinnvertible debenture that is being restock and look forward to continuit to ADC Therapeutics on this transaction that the proceeds to continue maximatologic malignancies and solid turn.  Announced  15-Aug-2022	wth. "Elise Wang, Partner, Head of g back to its successful IPO in May etired today. We are very pleased ing to support the company going fection.  Alizing the potential of ZYNLONTA and are respectively.	Private Equity Capital Markets a 2020 as both an equity investor in to take a significant portion of the prward." Morgan Stanley & Co. LLC
platform. This commitment of cap with the Company's leadership te Deerfield said: "We have been a s the IPO and also providing the cor repayment consideration in ADCT acted as the sole placement agent Deal Rationale ADC Therapeutics intends to use to antibody drug conjugates for hemo Deal Information Deal Status  Announced Date Deal Financials Deal Value (US\$ m) Securities Type Offered	eam during this next phase of grow upporter of ADC Therapeutics datin nvertible debenture that is being re stock and look forward to continuit to ADC Therapeutics on this transact the net proceeds to continue maximatologic malignancies and solid tum  Announced 15-Aug-2022  175 Other	wth. "Elise Wang, Partner, Head of g back to its successful IPO in May etired today. We are very pleased ing to support the company going fection.  Alizing the potential of ZYNLONTA and are respectively.	Private Equity Capital Markets a 2020 as both an equity investor is to take a significant portion of the prward." Morgan Stanley & Co. LL
platform. This commitment of cap with the Company's leadership te Deerfield said: "We have been a s the IPO and also providing the cor repayment consideration in ADCT acted as the sole placement agent Deal Rationale ADC Therapeutics intends to use t antibody drug conjugates for hemo Deal Information Deal Status  Announced Date Deal Financials Deal Value (US\$ m) Securities Type Offered Maturity Date	eam during this next phase of growupporter of ADC Therapeutics dating invertible debenture that is being restock and look forward to continuit to ADC Therapeutics on this transaction in the net proceeds to continue maximatologic malignancies and solid turn.  Announced  15-Aug-2022	wth. "Elise Wang, Partner, Head of g back to its successful IPO in May etired today. We are very pleased ing to support the company going fection.  Alizing the potential of ZYNLONTA and are respectively.	Private Equity Capital Markets a 2020 as both an equity investor is to take a significant portion of the prward." Morgan Stanley & Co. LL
platform. This commitment of cap with the Company's leadership to Deerfield said: "We have been a sthe IPO and also providing the correpayment consideration in ADCT acted as the sole placement agent Deal Rationale  ADC Therapeutics intends to use to antibody drug conjugates for hemodel Information  Deal Status  Announced Date  Deal Financials  Deal Value (US\$ m)  Securities Type Offered  Maturity Date	eam during this next phase of grow upporter of ADC Therapeutics datin nvertible debenture that is being re stock and look forward to continuit to ADC Therapeutics on this transact the net proceeds to continue maximatologic malignancies and solid tum  Announced 15-Aug-2022  175 Other	wth. "Elise Wang, Partner, Head of g back to its successful IPO in May etired today. We are very pleased ing to support the company going fection.  Alizing the potential of ZYNLONTA and are respectively.	Private Equity Capital Markets a 2020 as both an equity investor into take a significant portion of the prward." Morgan Stanley & Co. LLC
platform. This commitment of cap with the Company's leadership to Deerfield said: "We have been a sthe IPO and also providing the corepayment consideration in ADCT acted as the sole placement agent Deal Rationale  ADC Therapeutics intends to use transibody drug conjugates for hemodel Information  Deal Status  Announced Date  Deal Financials  Deal Value (US\$ m)  Securities Type Offered  Maturity Date  Companies Information	eam during this next phase of grow upporter of ADC Therapeutics datin nvertible debenture that is being re stock and look forward to continuit to ADC Therapeutics on this transact the net proceeds to continue maximatologic malignancies and solid tum  Announced 15-Aug-2022  175 Other	wth. "Elise Wang, Partner, Head of g back to its successful IPO in May etired today. We are very pleased ing to support the company going fection.  Alizing the potential of ZYNLONTA and are respectively.	Private Equity Capital Markets a 2020 as both an equity investor into take a significant portion of the prward." Morgan Stanley & Co. LLC
platform. This commitment of cap with the Company's leadership to Deerfield said: "We have been a sthe IPO and also providing the correpayment consideration in ADCT acted as the sole placement agent Deal Rationale  ADC Therapeutics intends to use to antibody drug conjugates for hemodel Information  Deal Status  Announced Date  Deal Financials  Deal Value (US\$ m)  Securities Type Offered  Maturity Date  Companies Information  Acquirer Company Information	eam during this next phase of grow upporter of ADC Therapeutics datin nvertible debenture that is being re stock and look forward to continuit to ADC Therapeutics on this transact the net proceeds to continue maxim atologic malignancies and solid tum  Announced  15-Aug-2022  175  Other  15-Aug-2029	wth. "Elise Wang, Partner, Head of g back to its successful IPO in May etired today. We are very pleased ing to support the company going fection.  Alizing the potential of ZYNLONTA and are respectively.	Private Equity Capital Markets a 2020 as both an equity investor into take a significant portion of the prward." Morgan Stanley & Co. LL



through its platform such as credit, GP Strategic capital and real estate. its credit executes and manages investments across various loan and equity-related instruments, gp strategic capital providing long-term minority equity and financing. Blue Owl provides flexible real estate solutions. It provides solutions to middle-market companies including alternative asset managers, financial advisors, growth tech

companies and institutional inves	stors, among others. The company	operates in the US, the UK, Malt	a, Hong Kong, Singapore and the
Cayman Islands. Blue Owl is heado	uartered in New York, the US.		
Company Name	Oaktree Capital Management LP	Parent	Brookfield Corp

#### **Business Description**

Oaktree Capital Management LP (Oaktree), a subsidiary of Brookfield Asset Management Inc, is a provider of alternative investment solutions. The company invests in liquid and illiquid instruments which include high yield bonds, convertible securities, leveraged loans, structured credit instruments, distressed and private debt; real estate assets; infrastructure related businesses. It's private equity strategies provides funds to undervalued companies across various sectors. Oaktree also provides capital to undervalued stocks through its emerging markets and value equity strategies. The company has operational presence across North America, Europe, Middle East, Asia, and Australia. Oaktree is headquartered in Los Angeles, California, the US.

Target Company Information		
Company Name	ADC Therapeutics SA	

#### **Business Description**

ADC Therapeutics SA (ADC Therapeutics) is a biotechnology company that develops antibody-drug conjugates (ADCs) to treat hematologic malignancies and solid tumors. It offers Zynlonta, a CD-19-directed antibody for treatment of e B-cell lymphoma in adult patients. The company is provides Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami). ADC Therapeutics develops ADCT-602 drug for Bcell acute lymphoblastic leukemia, ADCT-601 targeting AXL in solid tumors, ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular carcinoma, small cell lung cancer and myeloid leukemia. The company has operations in London, the UK and New Providence, and San Mateo, the US. ADC Therapeutics is headquartered in Lausanne, Switzerland.

Advisor Information		
Company Being Advised	Placement Agent	
ADC Therapeutics SA	Morgan Stanley & Co. LLC	
Source: GlobalData		



### **Private Equity**

### TSG Consumer Partners Invests in Specialty Dental Brands

TSG Consumer Partners Invests in Specialty Dental Brands			
Deal Type	Private Equity	Deal Sub Type	Direct Investment
Deal in Brief			
The investment will further strenguality of patient care.	ngthen SDB's ability to support the	best specialists in their unwaveri	ng mission to provide the highest
Deal Information			
Deal Status	Completed		
Completed Date	19-Sep-2022		
Companies Information			
Target Company Information			
Company Name	Specialty Dental Brands		
Investor Firm Information			
Firm Name	TSG Consumer Partners, LLC	Parent	Dyal Capital Partners
Business Description			
TSG Consumer Partners, LLC (TSG) is a private equity firm. The firm makes investments in early stage consumer companies. It provides acquisitions, management buyouts, corporate divestitures, liquidity and growth capital transactions. The firm's portfolio companies include Stumptown, Revolve, Dutch bros, Radio Systems, BrewDog, and Sexy hair, among others. TSG is headquartered in San Francisco, California, the US.  Advisor Information			
Company Being Advised	Legal Advisor		
Specialty Dental Brands	McGuire Woods LLP		
TSG Consumer Partners, LLC	Sidley Austin LLP		
	Ropes & Gray LLP		
Company Being Advised	Financial Advisor		
Specialty Dental Brands	Jefferies LLC		
TSG Consumer Partners, LLC	SVB Securities		
	William Blair & Company LLC		

Blue Owl Capital Inc (OWL) - Financial Analysis Review

Report Code: GDFS4572388FA Published: October 2023



	(Wealth Management)	
Source: GlobalData		



### Section 6 - Appendix

The data and analysis within this report is driven by GlobalData.

GlobalData gives you key information to drive sales, investment and deal making activity in your business.

Our coverage includes 200,000 + reports on 185,000+ companies (including 150,000+ private) across 200+ countries and 29 industries. The key industries include Alternative Energy, Oil & Gas, Clean Technology, Technology and Telecommunication, Pharmaceutical and Healthcare, Power, Financial Services, Chemical and Metal & Mining.

#### Methodology

GlobalData company reports are based on a core set of research techniques which ensure the best possible level of quality and accuracy of data. The key sources used include:

- · Company Websites
- · Company Annual Reports
- SEC Filings
- Press Releases
- · Proprietary Databases

Currency Codes	
Currency Code	Currency
USD	U.S. Dollars
GlobalData	

#### **Ratio Definitions**

#### **Capital Market Ratios**

Capital Market Ratios measure investor response to owning a company's stock and also the cost of issuing stock.

### Price/Earnings Ratio (P/E)

Price/Earnings (P/E) ratio is a measure of the price paid for a share relative to the annual income earned per share. It is a financial ratio used for valuation: a higher P/E ratio means that investors are paying more for each unit of income, so the stock is more expensive compared to one with lower P/E ratio. A high P/E suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E. Price per share is as of previous business close, and EPS is from latest annual report.

Calculation: Market Cap / Net Income

Enterprise
Value/Earnings before
Interest, Tax,
Depreciation &
Amortization
(EV/EBITDA)

Enterprise Value/EBITDA (EV/EBITDA) is a valuation multiple that is often used in parallel with, or as an alternative to, the P/E ratio. The main advantage of EV/EBITDA over the PE ratio is that it is unaffected by a company's capital structure. It compares the value of a business, free of debt, to earnings before interest. Price per share is as of previous business close, and shares outstanding last reported. Other items are from latest annual report.

Calculation: {(Market Cap + Debt + Minority Interest + Preferred Stock (Redeemable + Non-Redeemable) - Cash & Cash Equivalents)} / (Operating Income + Depreciation + Amortization)

### **Enterprise Value/Sales**

Enterprise Value/Sales (EV/Sales) is a ratio that provides an idea of how much it costs to buy the company's sales. EV/Sales is seen as more accurate than Price/Sales because market capitalization does not take into account the amount of debt a company has, which needs to be paid back at some point. Price per share is



as of previous business close, and shares outstanding last reported. Other items are from latest annual report.

Calculation: {(Market Cap + Debt + Minority Interest + Preferred Stock (Redeemable + Non-Redeemable) - Cash & Cash Equivalents)} / Revenue

### Enterprise Value/Operating Profit

Enterprise Value/Operating Profit measures the company's enterprise value to the operating profit. Price per share is as of previous business close, and shares outstanding last reported. Other items are from latest annual report.

Calculation: {(Market Cap + Debt + Minority Interest + Preferred Stock (Redeemable + Non-Redeemable) - Cash & Cash Equivalents)} / Operating Income

### Enterprise Value/Total Assets

Enterprise Value/Total Assets measures the company's enterprise value to the total assets. Price per share is as of previous business close, and shares outstanding last reported. Other items are from latest annual report.

Calculation: {(Market Cap + Debt + Minority Interest + Preferred Stock (Redeemable + Non-Redeemable) - Cash & Cash Equivalents)} / Total Assets

**Dividend Yield** 

Dividend Yield shows how much a company pays out in dividends each year relative to its share price. In the absence of any capital gains, the dividend yield is the return on investment for a stock. Calculation: Annual Dividend per Share / Price per Share

GlobalData

#### **Equity Ratios**

These ratios are based on per share value.

#### Earnings per Share (EPS)

Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock. EPS serves as an indicator of a company's profitability.

Calculation: Net Income / Weighted Average Shares

#### **Dividend per Share**

Dividend is the distribution of a portion of a company's earnings, decided by the board of directors, to a class of its shareholders.

### **Dividend Cover**

Dividend cover is the ratio of company's earnings (net income) over the dividend paid to shareholders.

Calculation: Earnings per share / Dividend per share

#### **Book Value per Share**

Book Value per Share measure used by owners of common shares in a firm to determine the level of safety associated with each individual share after all debts are paid accordingly.

Calculation: {Shareholders Equity - Preferred Stock (Redeemable + Non-Redeemable)} / Outstanding Shares

#### Cash Value per Share

Cash Value per Share is a measure of a company's cash (cash & equivalents on the balance sheet) that is determined by dividing cash & equivalents by the total shares outstanding.

Calculation: Cash & equivalents / Outstanding Shares

GlobalData

#### **Profitability Ratios**

Profitability Ratios are used to assess a company's ability to generate earnings, based on revenues generated or resources used. For most of these ratios, having a higher value relative to a competitor's ratio or the same ratio from a previous period is indicative that the company is doing well.

#### **Gross Margin**

Gross margin is the amount of contribution to the business enterprise, after paying for direct-fixed and direct-variable unit costs.

Calculation: (Gross Profit / Revenue)\*100

### **Operating Margin**

Operating Margin is a ratio used to measure a company's pricing strategy and operating efficiency.



Calculation: (Operating Income / Revenue) *100  Net Profit Margin is the ratio of net profits to revenues for a company or business segment - that show the profit Margin is the ratio of net profits to revenues for a company or business segment - that show the profit Margin is the ratio of net profits.
Not Drotit Margin
how much of each dollar earned by the company is translated into profits.  Calculation: (Net Profit / Revenue) *100
Profit Markup Profit Markup measures the company's gross profitability, as compared to the cost of revenue.  Calculation: Gross Income / Cost of Revenue
PBIT Margin (Profit Before Interest & Tax Margin shows the profitability of the company before interest expense taxation.  Calculation: {(Net Profit+Interest+Tax) / Revenue} *100
PBT Margin (Profit Before Tax Margin measures the pre-tax income over revenues.  Calculation: {Net Income Before Tax / Revenue} *100
Return on Equity measures the rate of return on the ownership interest (shareholders' equity) of the common stock owners.  Calculation: (Net Income / Shareholders Equity)*100
Return on Capital Employed is a ratio that indicates the efficiency and profitability of a company's capit investments. ROCE should always be higher than the rate at which the company borrows; otherwise as increase in borrowing will reduce shareholders' earnings.  Calculation: Operating Income / (Total Assets – Current Liabilities) * 100
Return on Assets  Return on Assets is an indicator of how profitable a company is relative to its total assets, the rat measures how efficient management is at using its assets to generate earnings.  Calculation: (Net Income / [Current Year Total Assets + Last Year Total Assets)/2])*100
Return on Fixed Assets  Return on Fixed Assets measures the company's profitability to its fixed assets (property, plant equipment).  Calculation: (Net Income / [Current Year Fixed Assets + Last Year Fixed Assets)/2]) * 100
Return on Working Capital  Return on Working Capital measures the company's profitability to its working capital.  Calculation: {Operating Income / (Current Assets-Current Liabilities)} * 100

Cost Ratios		
Cost ratios help to unders	tand the costs the company is incurring as a percentage of sales.	
Operating costs (% of Sales)	Operating costs as percentage of total revenues measures the operating costs that a company incurs compared to the revenues.  Calculation: (Operating Expenses / Revenue) *100	
Administration costs (% of Sales)	Administration costs as percentage of total revenue measures the selling, general and administrative expenses that a company incurs compared to the revenues.  Calculation: (Administrative Expenses / Revenue) *100	
Interest costs (% of Sales)	Interest costs as percentage of total revenues measures the interest expense that a company incurs compared to the revenues.  Calculation: (Interest Expenses / Revenue) *100	
GlobalData		



#### **Liquidity Ratios**

Liquidity ratios are used to determine a company's ability to pay off its short-terms debts obligations. Generally, the higher the value of the ratio, the larger the margin of safety that the company possesses to cover short-term debts. A company's ability to turn short-term assets into cash to cover debts is of the utmost importance when creditors are seeking payment. Bankruptcy analysts and mortgage originators frequently use the liquidity ratios to determine whether a company will be able to continue as a going concern.

#### **Current Ratio**

Current Ratio measures a company's ability to pay its short-term obligations. The ratio gives an idea of the company's ability to pay back its short-term liabilities (debt and payables) with its short-term assets (cash, inventory, receivables). The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point.

**Calculation: Current Assets / Current Liabilities** 

#### **Quick Ratio**

Quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets.

#### Calculation: (Current Assets - Inventories) / Current Liabilities

### Cash Ratio

Cash ratio is the most stringent and conservative of the three short-term liquidity ratio. It only looks at the most liquid short-term assets of the company, which are those that can be most easily used to pay off current obligations. It also ignores inventory and receivables, as there are no assurances that these two accounts can be converted to cash in a timely matter to meet current liabilities.

Calculation: {(Cash & Bank Balance + Marketable Securities) / Current Liabilities)}

GlobalData

### Leverage Ratios

Leverage ratios are used to calculate the financial leverage of a company to get an idea of the company's methods of financing or to measure its ability to meet financial obligations. There are several different ratios, but the main factors looked at include debt, equity, assets and interest expenses.

#### **Debt to Equity Ratio**

Debt to Equity Ratio is a measure of a company's financial leverage. The debt/equity ratio also depends on the industry in which the company operates. For example, capital-intensive industries tend to have a higher debt-equity ratio.

Calculation: Total Debt / Shareholders Equity

### Debt to Capital Ratio

Debt to capital ratio gives an idea of a company's financial structure, or how it is financing its operations, along with some insight into its financial strength. The higher the debt-to-capital ratio, the more debt the company has compared to its equity. This indicates to investors whether a company is more prone to using debt financing or equity financing. A company with high debt-to-capital ratios, compared to a general or industry average, may show weak financial strength because the cost of these debts may weigh on the company and increase its default risk.

Calculation: {Total Debt / (Total Debt + Shareholders Equity)}

#### **Interest Coverage Ratio**

Interest Coverage Ratio is used to determine how easily a company can pay interest on outstanding debt, calculated as earnings before interest & tax by interest expense.

Calculation: Operating Income / Interest Expenses

GlobalData

#### **Efficiency Ratios**

Efficiency ratios measure a company's effectiveness in various areas of its operations, essentially looking at maximizing its use of resources.

#### **Fixed Asset Turnover**

Fixed Asset Turnover ratio indicates how well the business is using its fixed assets to generate sales. A higher ratio indicates the business has less money tied up in fixed assets for each currency unit of sales revenue. A declining ratio may indicate that the business is over-invested in plant, equipment, or other fixed assets.



	Calculation: Revenue / [Current Year Fixed Assets + Last Year Fixed Assets)/2]
Asset Turnover	Asset turnover ratio measures the efficiency of a company's use of its assets in generating sales revenue to the company. A higher asset turnover ratio shows that the company has been more effective in using its assets to generate revenues.  Calculation: Revenue / [Current Year Total Assets + Last Year Total Assets)/2]
Current Asset Turnover	Current Asset Turnover indicates how efficiently the business uses its current assets to generate sales.  Calculation: Revenue / [Current Year Current Assets + Last Year Current Assets)/2]
Inventory Turnover	Inventory Turnover ratio shows how many times a company's inventory is sold and replaced over a period. A low turnover implies poor sales and, therefore, excess inventory. A high ratio implies either strong sales or ineffective buying.  Calculation: Cost of Goods Sold /[Current Year Inventory + Last Year Inventory)/2]
Working Capital Turnover	Working Capital Turnover is a measurement to compare the depletion of working capital to the generation of sales. This provides some useful information as to how effectively a company is using its working capital to generate sales.  Calculation: Revenue / (Current Assets – Current Liabilities)
Capital Employed Turnover	Capital employed turnover ratio measures the efficiency of a company's use of its equity in generating sales revenue to the company.  Calculation: Revenue / (Total Assets – Current Liabilities)
Capex to sales	Capex to Sales ratio measures the company's expenditure (investments) on fixed and related assets' effectiveness when compared to the sales generated.  Calculation: (Capital Expenditure / Sales) *100
Net income per Employee	Net income per Employee looks at a company's net income in relation to the number of employees they have. Ideally, a company wants a higher profit per employee possible, as it denotes higher productivity.  Calculation: Net Income / No. of Employees
Revenue per Employee	Revenue per Employee measures the average revenue generated per employee of a company. This ratio is most useful when compared against other companies in the same industry. Generally, a company seeks the highest revenue per employee.  Calculation: Revenue / No. of Employees
Efficiency Ratio	Efficiency Ratio is used to calculate a bank's efficiency. An increase means the company is losing a larger percentage of its income to expenses. If the efficiency ratio is getting lower, it is good for the bank and its shareholders.  Calculation: [Non-interest expense / (Net Interest Income + Non-Interest Income)] * 100
GlobalData	

#### Notes

- · Financial information of the company is taken from the most recently published annual reports or SEC filings
- · The financial and operational data reported for the company is as per the industry defined standards
- Revenue converted to USD at average annual conversion rate as of fiscal year end

#### About GlobalData

GlobalData is one of the world's leading providers of company operational data and strategic analysis, providing detailed information on tens of thousands of companies globally. Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge. Data is continuously updated and revised by large teams of research experts, so that it always reflects the latest events and information. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research material for this series and its other reports. GlobalData offers comprehensive geographic coverage across world's most important sectors, focusing particularly on energy and healthcare.



#### Contact Us

If you have any queries about this report or would like further information, please contact info@globaldata.com

#### Disclaimer

All Rights Reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData.

The data and analysis within this report is driven by GlobalData from its own primary and secondary research of public and proprietary sources and does not necessarily represent the views of the company profiled.

The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that GlobalData delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such GlobalData can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.